OR WAIT null SECS
September 17, 2021
Takeda’s Exkivity (mobocertinib) was approved by FDA for the treatment of patients with lung cancer.
BMG Pharma has signed an agreement with HTL for the development and commercialization of injectable products with sodium hyaluronate lipoate formate.
Apellis Pharmaceuticals has announced the top-line results from two Phase III studies, evaluating intravitreal pegcetacoplan as a treatment for geographic atrophy.
Symbiosis Pharmaceutical Services has successfully completed an on-site inspection, performed by the MHRA, of its expanded facility in Stirling, UK.
SGS has selected the European Centre for Clinical Research Training (ECCRT) for the provision of good manufacturing practice (GMP) training of its pharmacy team.
Exscientia has entered into a four-year agreement with the Bill & Melinda Gates Foundation for the development of small-molecule therapeutics that can tackle coronavirus and other viruses with pandemic potential.
GeneQuine Biotherapeutics has chosen Exothera to advance the development of its osteoarthritis gene therapy product candidate, GQ-303.
September 16, 2021
The joint venture with OSTHUS will expand PharmaLex’s IT consulting and system integration expertise.
CPC’s MicroCNX Series Connectors provide an alternative to tube welding at small tubing sizes.
AzurRx’s acquisition of First Wave Bio grants them access to their proprietary niclosamide formulations.